8-K: InMed Pharmaceuticals Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Pharmaceuticals announced its second quarter fiscal year 2025 financial results, highlighting progress in its pharmaceutical pipeline and commercial operations.

Summary

• InMed Pharmaceuticals reported a net loss of $2.6 million for the three months ended December 31, 2024, compared to a net loss of $1.5 million for the same period in the previous year.
• The increase in net loss was primarily driven by higher expenses related to pharmaceutical research and development activities, as well as financing costs.
• Pharmaceutical research and development and patent expenses were $1 million for the three months ended December 31, 2024, compared with $0.6 million for the three months ended December 31, 2023.
• General and administrative expenses were $1.6 million for the three months ended December 31, 2024, compared with $1.4 million for the three months ended December 31, 2023.
• As of December 31, 2024, the Company's cash, cash equivalents and short-term investments were $3.5 million, which compares to $6.6 million at June 30, 2024.
• BayMedica's commercial business generated revenues of $1.1 million for the three months ended December 31, 2024, compared to $1.2 million for the same period last year, reflecting a 10% decrease.
• Despite the decrease in revenues, BayMedica achieved a net income of $0.23 million, representing a 189% improvement over the same period last year.
• The company expects its cash will be sufficient to fund its planned operating expenses and capital expenditures through to the end of the second quarter of calendar year 2025, depending on the level and timing of BayMedica commercial revenues, as well as the level and timing of our operating expenses.
• The Board intends to initiate a search for an independent director to replace Ms. Grove as soon as reasonably practicable.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there are positive developments in the drug pipeline and BayMedica's profitability, the increased net loss and decreased revenue temper the overall outlook.

Positives

• BayMedica achieved a net income of $0.23 million, representing a 189% improvement over the same period last year.
• INM-901 demonstrated a reduction in several plasma and brain markers of neuroinflammation in a preclinical study.
• The selection of an intravitreal formulation for INM-089 marks a critical milestone in advancing the dry AMD program.

Negatives

• The company reported a net loss of $2.6 million for the quarter, an increase from the $1.5 million loss in the same period last year.
• BayMedica's commercial business generated revenues of $1.1 million, a 10% decrease compared to the same period last year.

Risks

• The company's cash is only expected to be sufficient to fund operations through the end of the second quarter of calendar year 2025, depending on the level and timing of BayMedica commercial revenues, as well as the level and timing of our operating expenses.
• The company's future performance is subject to risks and uncertainties, including those related to the development and commercialization of its drug candidates.

Future Outlook

The Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditures through to the end of the second quarter of calendar year 2025, depending on the level and timing of BayMedica commercial revenues, as well as the level and timing of our operating expenses.

Management Comments

• 'We are pleased with the steady progress across both our pharmaceutical pipeline and commercial operations,' said Eric A. Adams, InMed's Chief Executive Officer.
• Adams continued, 'BayMedica continues to streamline its supply chain and reduce operational costs as it transitions to a profitable business unit, despite a challenging market landscape.'

Industry Context

InMed is focused on developing small molecule drug candidates for diseases with high unmet medical needs, specifically targeting Alzheimer's disease and dry AMD, which are areas of significant research and development in the pharmaceutical industry.

Comparison to Industry Standards

• It is difficult to compare InMed's results to industry standards without knowing the specific stage of development of their drug candidates and the size of the companies they are being compared to.
• However, the company's focus on Alzheimer's disease and dry AMD aligns with current industry trends, as these are areas of significant unmet medical need.
• Companies like Biogen, Eli Lilly, and Roche are also heavily invested in Alzheimer's research, while companies like Novartis and Apellis are focused on dry AMD.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased revenue.
• Employees may be affected by cost-cutting measures at BayMedica.
• Customers of BayMedica may be affected by changes in the supply chain.

Next Steps

• The Company is evaluating additional parameters from the long-term in vivo study and is conducting further molecular analyses to better define the mechanisms of action and potential role of INM-901 in AD treatment.
• The Company is expected to report on these aspects of the study in the coming weeks.
• The Board intends to initiate a search for an independent director to replace Ms. Grove as soon as reasonably practicable.

Key Dates

Keywords

InMed Pharmaceuticals, Financial Results, INM-901, INM-089, BayMedica, Alzheimer's Disease, Dry AMD, Pharmaceuticals, Net Loss, Revenue